Executive Summary
- Suntory Holdings has decided to acquire 100% of the shares of Daiichi Sankyo Healthcare, a wholly owned subsidiary of Daiichi Sankyo, for approximately JPY 246.5 billion
- The acquisition will be carried out in three phases from 2026 to 2029, ultimately making it a wholly owned subsidiary
- This transaction represents a major strategic M&A move from Suntory’s core beverage and alcoholic drinks business into the healthcare sector
- Daiichi Sankyo will divest its OTC business to focus management resources on innovative pharmaceuticals, particularly in oncology
Purpose of M&A
Background of the Acquirer (Suntory Holdings)
- Japan’s domestic alcoholic beverage market is expected to decline in the mid-to-long term, prompting a need for portfolio transformation
- Suntory has already been expanding into health-related businesses, including supplements and wellness products
- The acquisition will enable the company to build an integrated business model combining beverages, health foods, and pharmaceuticals
- The strategic goal is to expand into the “self-care” domain, covering prevention through pre-treatment stages
Background of the Seller (Daiichi Sankyo)
- Daiichi Sankyo Healthcare has strong brand recognition in the OTC pharmaceutical market (e.g., cold medicines and pain relievers)
- Compared to prescription drugs, OTC businesses generally offer lower growth and capital efficiency
- Daiichi Sankyo is focusing on innovative drug development, especially in oncology
- The divestiture allows for better allocation of resources and optimization of its business portfolio
Objectives and Expected Outcomes
For Suntory:
- Acquire OTC pharmaceutical capabilities and achieve vertical integration in healthcare
- Leverage brand strength, product development, and marketing capabilities to create new markets
- Establish an integrated “self-care” business as a new growth driver
For Daiichi Sankyo:
- Improve capital efficiency by divesting non-core businesses
- Strengthen competitiveness by concentrating resources on high-growth R&D areas
The transaction can be characterized as a “portfolio restructuring M&A” for both parties
Transaction Terms
Transaction Terms
- Acquisition price: Approximately JPY 246.5 billion
- Target: 100% equity of Daiichi Sankyo Healthcare
- Structure: Phased share acquisition (multiple closings)
- Phase 1: 30% acquisition
- Phase 2: Additional 40% (total 70%, becoming a consolidated subsidiary)
- Phase 3: Remaining 30% (100%, full ownership)
- The phased approach helps mitigate integration risks and ensures a smoother transition
Schedule
Board approval date: April 15, 2026
Signing date: April 15, 2026
Planned acquisition schedule:
Phase 1: June 1, 2026 (30%)
Phase 2: June 1, 2027 (70%, consolidated subsidiary)
Phase 3: June 1, 2029 (100%, wholly owned subsidiary)
※ The schedule may change depending on regulatory approvals such as antitrust clearances
Key Takeaways
- This is a representative cross-industry M&A deal in which a beverage company enters the healthcare sector
- It reflects a broader trend among Japanese companies shifting toward health and wellness businesses
- The deal is also a classic example of strategic portfolio restructuring through “selection and concentration” by both buyer and seller
